You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for HM MUCUS DM MAX ER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for HM MUCUS DM MAX ER

Average Pharmacy Cost for HM MUCUS DM MAX ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.56382 EACH 2024-08-21
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.51117 EACH 2024-07-17
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.55176 EACH 2024-06-19
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.56466 EACH 2024-05-22
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.55836 EACH 2024-04-17
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.54120 EACH 2024-03-20
HM MUCUS DM MAX ER 1200-60 MG 62011-0423-01 0.56027 EACH 2024-02-21
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for HM MUCUS DM MAX ER

Introduction to Guaifenesin and HM MUCUS DM MAX ER

Guaifenesin, an expectorant commonly used to help clear mucus and phlegm from the airways, is a key ingredient in various cough and cold medications, including HM MUCUS DM MAX ER. This drug combines guaifenesin with dextromethorphan, a cough suppressant, to provide relief from coughs and chest congestion.

Global Guaifenesin Market Overview

The global guaifenesin market is projected to reach USD 95 million by 2027, growing at a Compound Annual Growth Rate (CAGR) of approximately 3.1% from 2022 to 2027[1][3].

Market Segmentation

By Application

The cough treatment drug segment, which includes products like HM MUCUS DM MAX ER, is the fastest-growing segment in the guaifenesin market. This segment is driven by the increasing need for respiratory health management, particularly post-pandemics like COVID-19. The broader expectorant drugs market, which includes guaifenesin-based products, is valued at USD 17,648.2 million in 2024 and is projected to reach USD 38,455.4 million by 2034, growing at a CAGR of 4.3% from 2024 to 2034[1].

By Product

HM MUCUS DM MAX ER falls under the extended-release tablet category, which is one of the product segments analyzed in the guaifenesin market. Extended-release formulations are gaining popularity due to their convenience and efficacy in managing symptoms over a longer period[3].

Demand Drivers

  • Growing Application in Cough Treatment: The increasing use of guaifenesin in cough treatment drugs, especially in hospitals and clinics, is a significant driver. For instance, the Indian pharmaceutical sector is expected to reach USD 65 billion by 2024 and around USD 120-130 billion by 2030, which will further boost the demand for guaifenesin[1].
  • Consumer Interest in Oral Medications: Increasing consumer interest in oral medications, including expectorants, contributes to the demand. China, with its reliance on traditional Chinese medicine and high incidence of respiratory diseases, is a key market[1].
  • Advancements in Hospital Infrastructure: The robust advancement in hospital infrastructure and innovation in drug delivery and processing projects will also boost the growth prospects for guaifenesin-based products[3].

Price Trends and Projections

Raw Material Costs

Fluctuations in the cost of raw materials such as glycerin and guaiacol can impact the final product price of HM MUCUS DM MAX ER. Any increase in these costs could lead to higher prices for the end product[1].

Regulatory Environment

Changes in regulatory standards related to pharmaceutical manufacturing and safety can affect production costs and subsequently prices. Stringent regulations against the use of cough suppressants may also influence pricing strategies[4].

Market Competition

The presence of substitutes and the overall competitive landscape in the expectorant drugs market can influence pricing strategies. For example, the availability of generic versions of similar drugs can drive prices down[2].

Regional Market Analysis

North America

The North American market, particularly the U.S., sees significant demand for guaifenesin due to high hospital drug expenses. According to the American Hospital Association, hospital drug expenses per adjusted discharge increased by 30.3% in 2020-21 compared to 2019[1].

Asia-Pacific

China is a key market with an anticipated CAGR of 8.1% for expectorant drugs by 2034. The country's healthcare system, which includes traditional Chinese medicine, drives the demand for expectorant herbs and medications. The Asia-Pacific region is expected to be the fastest-growing region for guaifenesin-based products, including HM MUCUS DM MAX ER[1][5].

Challenges and Opportunities

Availability of Substitutes

The global guaifenesin market faces challenges from the availability of substitute expectorants, which can impact market share and pricing. However, innovations in drug delivery and processing can enhance the efficacy and appeal of guaifenesin-based products, potentially leading to higher demand and stable or increasing prices[1][3].

Technological Advancements

Technological advancements in drug delivery and processing are expected to boost the growth prospects for guaifenesin. For instance, the FDA approval for new extended-release formulations like Mucinex DM Maximum Strength has driven market growth[4].

Pricing of HM MUCUS DM MAX ER

The pricing of HM MUCUS DM MAX ER can vary based on several factors, including the pharmacy, location, and availability of discounts.

  • Extended Release Formulations: For similar extended-release formulations like Mucus Relief DM, the cost can range from $13 to $20 for a supply of 20 tablets, depending on the pharmacy and any available discounts[2].

Key Takeaways

  • Fastest-Growing Segment: The cough treatment drug segment is the fastest-growing in the guaifenesin market.
  • Major End-Users: Multispecialty hospitals are the largest end-users of guaifenesin.
  • Global Market Growth: The global expectorant drugs market, including guaifenesin-based products, is expected to grow significantly due to increasing respiratory health concerns.
  • Regional Growth: Regional markets, especially in Asia-Pacific, are driving growth due to traditional medicine practices and high incidence of respiratory diseases.

FAQs

1. What is the projected market size of the global guaifenesin market by 2027? The global guaifenesin market is forecasted to reach USD 95 million by 2027[1].

2. Which segment is the fastest-growing in the guaifenesin market? The cough treatment drug segment is the fastest-growing, expected to grow at a CAGR of around 3.7% during the forecast period[1].

3. What is the significance of the multispecialty hospital segment in the guaifenesin market? The multispecialty hospital segment held the largest market share in 2021, with over 57% of the global guaifenesin market[1].

4. How does the broader expectorant drugs market impact guaifenesin-based products? The expectorant drugs market, valued at USD 17,648.2 million in 2024, is projected to reach USD 38,455.4 million by 2034, driving demand for guaifenesin-based products like HM MUCUS DM MAX ER[1].

5. What are the key drivers of the guaifenesin market? Key drivers include growing applications in cough treatment drugs, increasing consumer interest in oral medications, and advancements in hospital infrastructure and technology[1][3].

Sources Cited

  1. DrugPatentWatch: Market Analysis and Financial Projection for QC MUCUS RELIEF ER[1].
  2. Drugs.com: Mucus Relief DM Prices, Coupons, Copay Cards & Patient Assistance[2].
  3. IndustryARC: Guaifenesin Market Size Report, 2022-2027[3].
  4. Allied Market Research: Guaifenesin Market Size, Trends | Industry Report 2021 - 2030[4].
  5. DrugPatentWatch: Drug prices and trends for QC MUCUS RLF MAX[5].

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.